
Bioporto A/S
CSE:BIOPOR

Bioporto A/S
Revenue
Bioporto A/S
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Bioporto A/S
CSE:BIOPOR
|
Revenue
kr34.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
![]() |
Genmab A/S
CSE:GMAB
|
Revenue
kr21.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
32%
|
CAGR 10-Years
38%
|
|
![]() |
Zealand Pharma A/S
CSE:ZEAL
|
Revenue
kr62.7m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-9%
|
|
![]() |
Ascendis Pharma A/S
NASDAQ:ASND
|
Revenue
€363.6m
|
CAGR 3-Years
260%
|
CAGR 5-Years
94%
|
CAGR 10-Years
39%
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Revenue
kr6.1B
|
CAGR 3-Years
57%
|
CAGR 5-Years
61%
|
CAGR 10-Years
20%
|
|
![]() |
Saniona AB
STO:SANION
|
Revenue
kr26.7m
|
CAGR 3-Years
28%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

See Also
What is Bioporto A/S's Revenue?
Revenue
34.9m
DKK
Based on the financial report for Sep 30, 2024, Bioporto A/S's Revenue amounts to 34.9m DKK.
What is Bioporto A/S's Revenue growth rate?
Revenue CAGR 10Y
7%
Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Bioporto A/S have been 12% over the past three years , 4% over the past five years , and 7% over the past ten years .